A Randomized, Double-blind, 104-weeks Treatment Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of Telbivudine Oral Solution and Tablets in Children and Adolescents With Compensated HBeAg-positive and Negative Chronic Hepatitis B Virus Infection
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 05 Dec 2018
At a glance
- Drugs Telbivudine (Primary)
- Indications Hepatitis B
- Focus Registrational; Therapeutic Use
- Sponsors Novartis
- 28 Nov 2018 Planned End Date changed from 27 Dec 2019 to 31 Jan 2019.
- 28 Nov 2018 Planned primary completion date changed from 27 Dec 2019 to 31 Jan 2019.
- 04 Mar 2017 This trial has been discontinued in Greece.